Treace Medical Concepts (TMCI) reported $213M in revenue for fiscal 2025, +1.6% year on year. That ranks #2642 by revenue among 2853 SEC filers and #281 in Healthcare. It posted a net loss of −$59.0M for the same year. Revenue has grown 32.4% a year on average since 2019 ($39.4M then). The fiscal 2025 balance sheet shows $191M in total assets, $10.7M in cash and $55.6M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $213M | +1.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $170M | +0.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$54.2M | +$1.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$59.0M | −$3.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$16.0M | +$21.2M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $13.5M | +16.6% | FY20252025-12-31 |
| Total assetsAssets | $191M | −12.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $87.3M | −22.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $10.7M | −5.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $55.6M | +4.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $47.2M | −$18.0M | Open → |
| Q2 20262026-06-30 | $45.4M | −$15.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Treace Medical Concepts, Inc.
- Ticker
- TMCI
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001630627
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ideaya BiosciencesIDYA | $219M | −$114M |
| Vanda PharmaceuticalsVNDA | $216M | −$221M |
| AmarinAMRN | $214M | −$38.8M |
| Treace Medical ConceptsTMCI | $213M | −$59.0M |
| Establishment LabsESTA | $211M | −$51.1M |
| Canopy GrowthCGC | $204M | −$189M |
| Si-BoneSIBN | $201M | −$18.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Treace Medical Concepts — Key figures |url=https://companiesranked.com/en/company/treace-medical-concepts |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Treace Medical Concepts — Key figures. CompaniesRanked. https://companiesranked.com/en/company/treace-medical-conceptsBibTeX
@misc{companiesranked-en-company-treace-medical-concepts-2026,
author = {{CompaniesRanked}},
title = {{Treace Medical Concepts — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/treace-medical-concepts}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-079167 · February 27, 2026
{{cite web |title=Treace Medical Concepts — Key figures — 10-K (0001193125-26-079167) |url=https://www.sec.gov/Archives/edgar/data/1630627/000119312526079167/tmci-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.